Principal Financial Group Inc. Has $38,000 Stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Principal Financial Group Inc. lifted its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 116.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,759 shares of the biopharmaceutical company’s stock after acquiring an additional 12,225 shares during the period. Principal Financial Group Inc.’s holdings in Lexicon Pharmaceuticals were worth $38,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in LXRX. BNP Paribas Financial Markets lifted its holdings in shares of Lexicon Pharmaceuticals by 82.6% during the first quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 26,859 shares during the period. Vanguard Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock valued at $15,363,000 after acquiring an additional 420,854 shares during the period. Virtu Financial LLC acquired a new position in Lexicon Pharmaceuticals in the first quarter valued at about $105,000. Hennion & Walsh Asset Management Inc. bought a new stake in Lexicon Pharmaceuticals in the 2nd quarter valued at $912,000. Finally, BVF Inc. IL raised its holdings in shares of Lexicon Pharmaceuticals by 22.2% in the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock valued at $37,387,000 after purchasing an additional 4,440,300 shares during the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Down 4.1 %

Lexicon Pharmaceuticals stock opened at $1.63 on Tuesday. The company has a current ratio of 11.51, a quick ratio of 11.49 and a debt-to-equity ratio of 0.41. The firm’s fifty day moving average price is $1.83 and its two-hundred day moving average price is $1.88. The firm has a market capitalization of $401.37 million, a price-to-earnings ratio of -1.96 and a beta of 1.33. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.92 and a 1-year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. The firm had revenue of $1.65 million during the quarter, compared to analyst estimates of $2.74 million. During the same quarter last year, the business earned ($0.22) earnings per share. On average, equities research analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on LXRX shares. StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a research note on Tuesday, July 9th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $7.50.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.